尔康制药：10月29日召开董事会会议

Group 1 - The company Erkang Pharmaceutical (SZ 300267) held its 16th meeting of the 5th Board of Directors on October 29, 2025, to review documents including the proposal to amend the company's articles of association [1] - For the first half of 2025, the revenue composition of Erkang Pharmaceutical was as follows: 79.38% from the pharmaceutical industry, 18.57% from the new energy sector, and 2.05% from other businesses [1]